34786197|t|Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy.
34786197|a|Clinicians should be aware of the potential for the pharmacologic activity of SGLT2 inhibitors to persist long after the standard drug clearance period of five half-lives, the typical duration used to guide pre-operative medication recommendations.
34786197	10	17	ketosis	Disease	MESH:D007662
34786197	22	32	glycosuria	Disease	MESH:D006029

